Note


γ -Amino Alcohols via Organocascade Reactions Involving Dienamine Catalysis

Chandrakumar Appayee, Americo J. Fraboni, and Stacey E. Brenner-Moyer*

Department of Chemistry, Brooklyn College and the City University of New York, 2900 Bedford Avenue, Brooklyn, New York 11210, United States

Supporting Information


ABSTRACT: Whereas cascade reactions catalyzed by secondary amines combine iminium- and/or enamine-catalyzed reactions, we introduce the feasibility of combining these modes of catalysis with dienamine-catalysis as a new general mechanism for cascade reactions. Enantioenriched β -functionalized- γ -amino alcohols were produced from simple achiral enals in one flask by combining dienamine- and iminiumcatalyzed intermolecular reactions. Reaction products are



precursors of γ -amino acids, γ -lactams, and pyrrolidines; one was employed in a synthesis of γ -amino acid (S)-vigabatrin, the bioactive enantiomer of Sabril.

In recent years, organocascade reactions have been established as efficient green chemical methods for rapidly building molecular complexity.¹⁻⁴ Cascade reactions catalyzed by chiral secondary amines (1, Scheme 1) entail some combination of iminium- and/or enamine-catalysis. For example, in a typical cascade reaction catalyzed by 1, an α,β -unsaturated aldehyde is sequentially functionalized at the β - and α -positions via iminium- and enamine-catalyzed reactions, respectively (eq 1, Scheme 1).^{1,2} While iminium- and


Scheme 1. Reactions Catalyzed by Chiral Secondary $Amines^a$




^{*a*}Eq 1: organocascade reactions via iminium- and enamine-catalysis; eq 2: γ -functionalization via dienamine catalysis; eq 3: proposed organocascade reaction via dienamine- and iminium-catalysis.

enamine-catalysis are well-established modes of catalysis for chiral secondary amines, dienamine catalysis is a relatively underexplored mode of catalysis for these catalysts. Perhaps this is because dienamine intermediates of type 6 are prone to multiple reaction motifs, rendering deliberate manipulation of their reactivity challenging. For example, the olefin(s) in dienamines can react to generate formal [2 + 2] and [4 + 2] cycloaddition products.⁵⁻¹² Alternatively, both the α - and γ carbons of dienamine 6 are nucleophilic, and either position can react with discrete electrophiles.¹³⁻²⁵ There are four examples of dienamine catalyzed reactions producing γ functionalized- $\alpha_{,\beta}$ -unsaturated carbonyl compounds (eq 2, Scheme 1).^{20,23-25} We suspected that γ -functionalized- $\alpha_{,\beta}$ unsaturated aldehydes of type 7 would be suitable substrates for subsequent iminium-catalyzed intermolecular reactions (eq 3, Scheme 1). This straightforward but heretofore unexplored transformation is significant because, if successful, it would introduce the feasibility of organocascade reactions entailing some combination of iminium- and enamine-catalysis with dienamine catalysis. Organocascade reactions proceeding by these novel mechanisms would generate functionalized aldehyde products that are not directly accessible via current organocascade reactions. We report herein the first example of a cascade reaction combining dienamine- and iminiumcatalyzed intermolecular reactions. This organocascade reaction directly produces γ -amino alcohols, which are valuable synthetic precursors of γ -amino acids and substituted γ -lactams and pyrrolidines. In fact, one cascade product was employed in a formal synthesis of non-natural γ -amino acid (S)-vigabatrin, the biologically active enantiomer of the racemic anticonvulsant drug marketed as Sabril.²⁶

Received: August 13, 2012 Published: September 12, 2012






^aReaction conditions for step 1: 2a (1.5 equiv), 10a, 1a (0.1 equiv), $PhCO_2H$ (0.1 equiv), solvent, rt. Reaction conditions for step 2: (i) 11, 12 (1.1 equiv), 1a (0.1 equiv), $PhCO_2H$ (0.1 equiv), solvent (0.25 M), temp; (ii) NaBH₄ (4.5 equiv), MeOH, 0 °C. ^{b1}H NMR yield using internal standard. ^cDetermined by chiral phase HPLC of derivative of (corresponding) alcohol. ^dIsolated yield. ^eDetermined by chiral phase HPLC of its corresponding 4-chlorobenzoyl derivative, 22a. ^fReaction time was 5 h. Longer reaction times led to product decomposition at this temperature. ^gReaction conditions: (i) 2a (1.5 equiv), 10a, 1a (0.1 equiv), PhCO₂H (0.2 equiv), solvent, rt; (ii) 12 (1.5 equiv), 1a (0.1 equiv), 0 °C; (iii) NaBH₄ (6 equiv), MeOH, 0 °C.

Both steps of the proposed cascade reaction were initially optimized independently to identify a common set of reaction conditions that would be suitable for a one-pot cascade reaction (Table 1). Catalyst 1a was found to be effective for both steps. Next, both steps were evaluated in the optimal solvents for the γ -amination (toluene) and conjugate reduction (CHCl₃) reactions (entries 1–4).^{20,27} While the γ -amination proceeded in either solvent, the conjugate reduction was ineffective in toluene; the Hantzsch ester was insoluble in this solvent at low temperature, and product decomposition was observed in this solvent at rt. Thus, CHCl₃ was identified as the optimal solvent for the cascade reaction. While a number of variables were examined in an effort to improve the yield of the first step,²⁸ the variable that was most impactful was reaction concentration (entries 3, 5-7). In our hands, more dilute reaction conditions led to higher yields in the γ -amination reaction. Interestingly, this is opposite the trend observed by Jørgensen (in toluene and CH₂Cl₂) for this reaction.²⁰ Ultimately optimal reaction conditions for the one-pot cascade reaction were identified,²⁸ which provided γ -amino alcohol 13a in a single flask from 2a in 63% yield and 92% ee (entry 8).²⁹

With optimal reaction conditions for the one-pot cascade reaction in hand, a variety of other α_{β} -unsaturated aldehydes were examined in this transformation (Table 2). Enals with unbranched aliphatic R groups provided y-amino alcohols in excellent yield (≥89% average yield per step) and ee (entries 1-3). Sterically demanding substituents at the δ -position of enals were tolerated in this transformation (entries 4, 5), while bulky substitution at the γ -position (R = *i*Pr) was not (data not shown). A heteroatom at the δ -position of enals was also tolerated (entry 6). The use of dibenzyl azodicarboxylate (DBAD; $R^1 = Bn$) required that the second step of the cascade reaction be run at lower temperatures to prevent product decomposition and resulted in lower yields and slightly lower ee's (entry 7 vs entry 2). γ -Amino alcohol 13i was generated in lower yield (72% average yield per step) and lower, but still good, ee (entry 8). Use of enals with related δ -substituents (R =




^{*a*}Reaction conditions: (i) **2** (0.375 mmol), **10** (0.25 mmol), **1a** (0.025 mmol), PhCO₂H (0.050 mmol), CHCl₃ (1 mL), rt, 16–48 h; (ii) **12** (0.375 mmol), **1a** (0.025 mmol), 0 °C, 20–48 h; (iii) NaBH₄ (1.5 mmol), MeOH, 0 °C. ^{*b*}Isolated yield. ^{*c*}Determined by chiral phase HPLC of alcohol or of its corresponding 4-chlorobenzoyl derivative, **22**. ^{*d*}Step ii of cascade run at -20 °C. ^{*e*}Reaction run on 2.5 mmol (of **10**) scale.

CH₂OTBS and CH₂OMOM) gave similar results (data not shown). This is possibly due to the combination of the use of DBAD and the inductive effect of the electronegative oxygen at the δ -position of the enal, which reduces the nucleophilicity of the adjacent, γ -position of the dienamine in the first step of the cascade reaction. Nonetheless, the reaction with this substrate was readily scalable (entry 9). Finally, this transformation was also compatible with remote reactive functionality (entry 10).

Cascade product 13i was elaborated to produce (S)vigabatrin, the biologically active enantiomer of the racemic anticonvulsant drug Sabril (Scheme 2). It was found that

Scheme 2. Synthesis of (S)-Vigabatrin from Cascade Product 13i




protection of the alcohol in 13i was necessary for the tandem carbamate removal/N–N bond cleavage to proceed smoothly. Alcohol 13i was therefore protected as a TBS ether (14). Tandem carbamate removal/N–N bond cleavage, followed by Boc protection of the resulting free amine produced 15. Removal of the benzyl ether generated alcohol 16, which underwent a two-step, oxidation/Wittig olefination protocol to furnish 17. Deprotection of the TBS ether afforded alcohol 18. Oxidation and in situ lactam formation produced 19, a known penultimate intermediate in the total synthesis of (*S*)-vigabatrin.³⁰


Comparison of the optical rotation of γ -lactam 19 to the literature value established the configuration of 19, and of the corresponding stereocenter in cascade product 13i. The configurations of all other cascade products were assigned by analogy.

Thus, this formal synthesis of (S)-vigabatrin started from a simple achiral α,β -unsaturated aldehyde, and utilized a cascade reaction combining dienamine- and iminium-catalysis both to install the γ -amino functionality and to establish the γ -stereocenter. Presumably, this strategy could be employed in the synthesis of other non-natural γ -amino acids (or substituted γ -lactams or pyrrolidines). Inherent in this strategy is the ability to access either enantiomer of a γ -amino acid from the same starting material simply by using the appropriate enantiomer of the catalyst in the cascade reaction.

Finally, this cascade reaction is amenable to the use of nucleophiles other than 12, such as oxime 20 (Scheme 3).³¹ This result is illustrative of the capacity of cascade reactions combining dienamine- and iminium catalysis to generate enantiopure $\gamma_{\mu}\beta$ -difunctionalized alcohol products.

In conclusion, we have developed the first cascade reaction combining dienamine- and iminium-catalyzed intermolecular reactions. This cascade reaction produces enantioenriched γ amino alcohols and was the key step in a formal synthesis of the γ -amino acid (S)-vigabatrin, the bioactive enantiomer of the anticonvulsant drug, Sabril. Additionally, this cascade reaction was readily adapted to provide an enantiopure β -functionalized- γ -amino alcohol, thereby demonstrating that the combination of dienamine- and iminium-catalyzed reactions is a new, general mechanism for organocascade reactions. Organocascade





^aReaction conditions: (i) **2c** (0.375 mmol), **10a** (0.25 mmol), **1a** (0.025 mmol), PhCO₂H (0.025 mmol), toluene (0.125 mL), rt, 21 h; (ii) **20** (1.125 mmol), **1a** (0.025 mmol), PhCO₂H (0.025 mmol), 0 °C, 21 h; (iii) NaBH₄ (0.565 mmol), MeOH, 0 °C.

reactions of this type furnish useful molecular scaffolds that cannot be accessed directly by existing organocascade reactions.

EXPERIMENTAL SECTION

General Information. NMR data were acquired on a 400 MHz NMR spectrometer and use the following abbreviations: s = singlet, d = doublet, t = triplet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublets of doublets, brm = broad multiplet, brs = broad singlet. Ee's were determined using chiral phase HPLC with Chiralpak AD-H (0.46 × 25 cm) and Chiralpak AS-H (0.46 × 25 cm) columns. HRMS spectra were acquired using an MS spectrometer with Q-TOF mass analyzer. Flash chromatography was carried out with F60, 40–63 mm, 60 Å silica gel and EMD silica 60 F₂₅₄ glass TLC plates. Solvents were dried and kept air-free in a solvent purification unit, and were evaporated using a standard rotovapor and high vacuum. All reactions were carried out in oven-dried glassware, under an Ar atmosphere. All enals were distilled freshly before use.

Preparation of Catalyst (1a), Enals (2e–g,i–j), and Oxime (20). Catalyst $1a^{32}$ was prepared from the corresponding diary-lprolinol³³ using a known procedure. Enals $2e_i^{34} 2f_i^{35} 2g_i^{35} 2i_i^{36}$ and $2j_i^{37}$ and oxime 20^{38} were prepared using known procedures.

General Procedure for Dienamine-Iminium Cascade. To a mixture of catalyst 1a (15 mg, 0.025 mmol) and benzoic acid (6 mg, 0.05 mmol) was added CHCl₃ (1 mL), and the mixture was stirred at rt. After 5 min enal 2 (0.375 mmol) was added. After 10 min 10 (0.25 mmol) was added, and the reaction was stirred in the dark until complete consumption of 10 as observed by ¹H NMR. The reaction was cooled to 0 °C, catalyst 1a (15 mg, 0.025 mmol) was added followed by 12 (95 mg, 0.375 mmol), and the reaction was stirred at 0 °C until complete consumption of enal as observed by ¹H NMR. The reaction was diluted with MeOH (2.5 mL), NaBH₄ (57 mg, 1.5 mmol) was added in portions, and the mixture was stirred at 0 °C for 30 min and then quenched with saturated NH₄Cl and extracted with CH₂Cl₂ $(3 \times 15 \text{ mL})$. The combined organic layers were dried over MgSO₄ and filtered. After removal of solvent under reduced pressure, the residue was purified by flash chromatography (EtOAc:petroleum ether) to yield γ -amino alcohol 13.

(*R*)-Diethyl 1-(5-hydroxypentan-2-yl)hydrazine-1,2-dicarboxylate (13a). Colorless oil (41 mg, 63%): $[\alpha]_D^{22} = -9.9$ (c = 0.55 in CHCl₃); IR (thin film, KBr) 3292, 2982, 2936, 1710, 1523, 1418, 1379, 1236, 1058, 761 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.48 (brm, 1H), 4.21–4.09 (m, 5H), 3.67–3.60 (m, 2H), 1.88 (brs, 1H), 1.72–1.62 (m, 2H), 1.42–1.40 (m, 1H), 1.28–1.21 (m, 6H), 1.14 (d, J = 6.4 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.4, 156.3, 62.6, 62.6, 62.2, 53.5, 30.3, 29.5, 18.4, 14.6, 14.5 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₁H₂₃N₂O₅] 263.1607, found 263.1603.

(*R*)-Diethyl 1-(6-hydroxyhexan-3-yl)hydrazine-1,2-dicarboxylate (13b). Colorless oil (50 mg, 72%): $[\alpha]_D^{23} = 4.5$ (c = 1.2 in CHCl₃); IR (thin film, KBr) 3284, 2979, 2935, 1693, 1525, 1416,1383, 1262, 1058, 937 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.14–6.67 (m, 1H), 4.15–3.87 (m, 5H), 3.61–3.53 (m, 2H), 2.53 (brs, 1H), 1.55–1.39 (m, 6H), 1.24–1.20 (m, 6H), 0.87 (brs, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.6/157.4, 157.1/156.8, 62.6, 62.3, 62.0, 60.8/

59.6, 29.5, 28.5, 25.8/25.7, 14.5, 14.4, 11.1 ppm; HRMS (ESI) $[M + H]^+$ calcd. for $[C_{12}H_{25}N_2O_5]$ 277.1763, found 277.1766.

(*R*)-Diethyl 1-(1-hydroxyheptan-4-yl)hydrazine-1,2-dicarboxylate (13c). Colorless oil (51 mg, 70%): $[\alpha]_D^{23} = 3.6$ (c = 1.0 in CHCl₃); IR (thin film, KBr) 3466, 3283, 2960, 2933, 1711, 1417, 1257, 1060, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.35 (brm, 1H), 4.21–4.03 (m, 5H), 3.67–3.59 (m, 2H), 1.80–1.42 (m, 8H), 1.29–1.25 (m, 6H), 0.90 (t, J = 6.8 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.5/157.1, 156.5, 62.4, 62.4, 62.1, 58.4/57.5, 34.9, 29.5, 28.7, 19.7, 14.5, 14.4, 13.9 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₃H₂₇N₂O₅] 291.1920, found 291.1920.

(*R*)-Diethyl 1-(1-hydroxyundecan-4-yl)hydrazine-1,2-dicarboxylate (13d). Colorless oil (62 mg, 72%): $[\alpha]_{\rm D}^{23} = 3.8$ (*c* = 1.58 in CHCl₃); IR (thin film, KBr) 3453, 3277, 2926, 2856, 1757, 1712, 1416, 1260, 1062, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.44 (brm, 1H), 4.18–3.99 (m, 5H), 3.66–3.57 (m, 2H), 1.99–1.24 (m, 16H), 1.28–1.24 (m, 6H), 0.86 (t, *J* = 6.6 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.6/157.2, 157.1/156.7, 62.5, 62.2, 62.1, 58.9/ 57.9, 32.8, 31.9, 29.5, 29.4, 28.8, 26.6, 22.8, 14.6/14.5, 14.2 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₇H₃₅N₂O₅] 347.2546, found 347.2555.

(5)-Diethyl 1-(1-hydroxy-6-methylheptan-4-yl)hydrazine-1,2-dicarboxylate (13e). Colorless oil (43 mg, 57%): $[\alpha]_D^{23} = 1.9$ (c = 2.12 in CHCl₃); IR (thin film, KBr) 3465, 3284, 2957, 2870, 1756, 1711, 1417, 1259, 1062, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.39 (brm, 1H), 4.19–4.17 (m, 5H), 3.67–3.58 (m, 2H), 1.96–1.11 (m, 8H), 1.29–1.25 (m, 6H), 0.90–0.88 (m, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.8, 157.3/156.7, 62.8, 62.7, 62.5, 57.1/ 56.0, 42.3/42.0, 29.8/29.3, 25.4/25.2, 23.6, 22.5/22.2, 14.8 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₄H₂₉N₂O₅] 305.2076, found 305.2072.

(S)-Diethyl 1-(5-hydroxy-1-phenylpentan-2-yl)hydrazine-1,2-dicarboxylate (13f). Colorless oil (41 mg, 49%): $[\alpha]_D^{23}$ = 14.4 (*c* = 0.94 in CHCl₃); IR (thin film, KBr) 3285, 2981, 2929, 1712, 1414, 1291, 1233, 1063, 758, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31–7.19 (m, 5H), 6.31 (brm, 1H), 4.58–4.07 (m, 5H), 3.67–3.58 (m, 2H), 2.85–2.79 (m, 2H), 2.05–1.51 (m, 4H), 1.30–1.18 (m, 7H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.8/157.2, 156.7/156.4, 138.5, 128.9, 128.7, 126.7, 62.6, 62.4, 60.3, 39.6.1/39.3, 29.5, 28.3, 14.6 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer t_R = 39.6 min, minor enantiomer t_R = 33.5 min; HRMS (ESI) [M + H]⁺ calcd. for [C₁₇H₂₇N₂O₅] 339.1920, found 339.1920.

(S)-Diethyl 1-(5-hydroxy-1-(methylthio)pentan-2-yl)hydrazine-1,2-dicarboxylate (13g). Colorless oil (35 mg, 45%): $[\alpha]_{\rm D}^{23} = 31.5$ (c = 1.07 in CHCl₃); IR (thin film, KBr) 3465, 3284, 2980, 2922, 2871, 1712, 1414, 1331, 1249, 1063, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.47 (brm, 1H), 4.39–4.16 (m, 5H), 3.68–3.60 (m, 2H), 2.58 (brs, 2H), 2.08 (s, 3H), 2.02 (brs, 1H), 1.83–1.52 (m, 3H), 1.27 (t, J = 7.0 Hz, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.8/157.3, 156.9/156.8, 62.9, 62.7, 62.3, 57.3/55.8, 37.3/36.7, 29.6, 28.3, 15.5/15.2, 14.6 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₂H₂₅N₂O₅S] 309.1484, found 309.1492.

(*R*)-Dibenzyl 1-(1-hydroxyheptan-4-yl)hydrazine-1,2-dicarboxylate (13h). White solid (46 mg, 44%): mp 83–84 °C; $[\alpha]_D^{24}$ = 4.4 (c = 1.6 in CHCl₃); IR (thin film, KBr) 3280, 3033, 2958, 2872, 1711, 1455, 1413, 1258, 1216, 1050, 740, 697 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (brs, 10H), 6.81 (brm, 1H), 5.68–4.65 (m, 4H), 4.23–4.05 (m, 1H), 3.57–3.34 (m, 2H), 2.10 (brs, 1H), 1.62–1.23 (m, 7H), 0.89–0.71 (m, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.3/157.0, 156.9/156.4, 136.2/136.0, 135.7, 128.6, 128.7, 128.6, 128.5, 128.3, 128.2, 127.8, 68.4/68.1, 67.9, 62.5, 59.0/57.9, 34.9, 29.5, 28.7, 19.7, 14.0 ppm; HPLC with an AD-H column (*n*-hexane/*i*-PrOH = 90:10), 1.0 mL/min; major enantiomer t_R = 23.0 min, minor enantiomer t_R = 28.3 min; HRMS (ESI) [M + H]⁺ calcd. for [C₂₃H₃₁N₂O₅] 415.2233, found 415.2228.

(S)-Dibenzyl 1-(1-(benzyloxy)-5-hydroxypentan-2-yl)hydrazine-1,2-dicarboxylate (13i). Colorless oil (46 mg, 37%): $[\alpha]_{D}^{26} = 7.2$ (c = 1.7 in CHCl₃); IR (thin film, KBr) 3279, 3032, 2942, 2867, 1713, 1498, 1454, 1411, 1218, 1091, 739, 697 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (brs, 15H), 6.53–6.24 (brm, 1H), 5.20– 4.96 (m, 4H), 4.54–4.38 (m, 3H), 3.68–3.38 (m, 4H), 1.97–1.27 (m, 4H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.4, 156.9, 138.0, 136.1, 135.7, 128.7, 128.6, 128.5, 128.2, 127.9, 127.8, 72.8, 69.6, 68.4/68.1, 67.9, 62.2, 58.4/56.9, 29.4, 24.7 ppm; HPLC with an AS-H column (*n*hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_{\rm R}$ = 83.5 min, minor enantiomer $t_{\rm R}$ = 74.3 min; HRMS (ESI) [M + H]⁺ calcd. for [C₂₈H₃₃N₂O₆] 493.2339, found 493.2328.

(*R*)-Diethyl 1-(8-cyano-1-hydroxyoctan-4-yl)hydrazine-1,2dicarboxylate (13j). Colorless oil (36 mg, 44%): $[\alpha]_D^{23} = 8.9$ (c = 1.62 in CHCl₃); IR (thin film, KBr) 3473, 3285, 2934, 2869, 2246, 1752, 1708, 1417, 1260, 1233, 1058, 761 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.74 (brm, 1H), 4.19–4.00 (m, 5H), 3.65–3.58 (m, 2H), 2.33 (t, J = 6.6 Hz, 2H), 2.10 (brs, 1H), 1.91–1.24 (m, 10H), 1.26 (t, J = 7.0 Hz, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 157.6, 157.1/ 156.7, 119.9, 62.8, 62.6, 62.2, 58.6/57.4, 32.2/31.9, 29.3/28.8, 25.7, 25.3, 17.1, 14.6 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₅H₂₈N₃O₅] 330.2029, found 330.2030.

General Procedure for Preparation of Esters 22a–e, 22g, 22j. To alcohol 13 (1 equiv) in CH_2Cl_2 (0.1 M) was added Et_3N (1.3 equiv) and 4-chlorobenzoyl chloride (1.3 equiv). After disappearance of alcohol by TLC, the solvent was removed under reduced pressure, and the product was purified by flash chromatography (EtOAc/ petroleum ether).

(*R*)-Diethyl 1-(5-((4-chlorobenzoyl)oxy)pentan-2-yl)hydrazine-1,2-dicarboxylate (22a). Colorless oil (62 mg, 78%): $[\alpha]_{\rm D}^{22} = -8.8$ (c = 1.02 in CHCl₃); IR (thin film, KBr) 3300, 2980, 2934, 1756, 1720, 1595, 1405, 1274, 1172, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.28 (brs, 1H), 4.31 (t, J = 6.4 Hz, 2H), 4.32–4.17 (m, 5H), 1.90– 1.67 (m, 3H), 1.48 (brs, 1H), 1.28–1.23 (m, 6H), 1.60 (d, J = 6.8 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.4, 156.1, 139.4, 131.1, 128.9, 128.8, 65.2, 62.5, 62.1, 53.4, 30.6, 25.8, 18.3, 14.6, 14.5 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_{\rm R} = 28.7$ min, minor enantiomer $t_{\rm R} = 38.9$ min; HRMS (ESI) [M + H]⁺ calcd. for [C₁₈H₂₆ClN₂O₆] 401.1479, found 401.1477.

(*R*)-Diethyl 1-(6-((4-chlorobenzoyl)oxy)hexan-3-yl)hydrazine-1,2-dicarboxylate (22b). Colorless oil (42 mg, 84%): $[\alpha]_{\rm D}^{23} = -9.6$ (c = 0.7 in CHCl₃); IR (thin film, KBr) 3296, 2978, 2934, 1757, 1718, 1595, 1405, 1274, 1093, 1015, 928 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.13 (brs, 1H), 4.32 (t, J = 6.4 Hz, 2H), 4.19–3.97 (m, 5H), 1.99 (brs, 1H), 1.82 (brs, 1H), 1.53–1.41 (m, 4H), 1.29–1.21 (m, 6H), 0.90 (brs, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.5/ 157.2, 156.8/156.7, 139.4, 131.1, 129.1, 128.8, 65.2, 62.5, 62.2, 60.3/ 59.4, 29.0/28.9, 25.9, 25.7/25.6, 14.7, 14.6, 11.2 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_{\rm R} = 15.9$ min, minor enantiomer $t_{\rm R} = 25.2$ min; HRMS (ESI) [M + H]⁺ calcd. for [C₁₉H₂₈ClN₂O₆] 415.1636, found 415.1638.

(*R*)-Diethyl 1-(1-((4-chlorobenzoyl)oxy)heptan-4-yl)hydrazine-1,2-dicarboxylate (22c). Colorless oil (82 mg, 91%): $[\alpha]_{\rm D}^{24} = -10.5$ (c = 1.4 in CHCl₃); IR (thin film, KBr) 3293, 2961, 2933, 1757, 1717, 1274, 1093, 1015, 851 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 6.25–6.18 (brm, 1H), 4.38–4.16 (m, 5H), 4.31 (t, J = 6.4 Hz, 2H), 1.99 (brs, 1H), 1.81–1.50 (m, 7H), 1.41–1.28 (m, 6H), 0.90 (t, J = 6.4 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.4/157.1, 156.8/ 156.5, 139.4, 131.1, 129.0, 128.8, 65.2, 62.7/62.5, 62.2, 58.1/57.3, 34.9, 29.2, 25.9, 19.7, 14.6, 14.5, 14.0 ppm; HPLC with an AS-H column (n-hexane/i-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_{\rm R} = 13.2$ min, minor enantiomer $t_{\rm R} = 18.9$ min; HRMS (ESI) [M + H]⁺ calcd. for [$C_{20}H_{30}$ ClN₂O₆] 429.1792, found 429.1788.

(*R*)-Diethyl 1-(1-((4-chlorobenzoyl)oxy)undecan-4-yl)hydrazine-1,2-dicarboxylate (22d). Colorless oil (33 mg, 49%): $[\alpha]_D^{23} = -8.8$ (c = 1.0 in CHCl₃); IR (thin film, KBr) 3299, 2957, 2928, 2856, 1759, 1721, 1405, 1274, 1228, 1118, 1104, 1093, 761 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.13 (brm, 1H), 4.33–4.05 (m, 5H), 4.31 (t, J =6.4 Hz, 2H), 2.00–1.25 (m, 16H), 1.29–1.25 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.4/157.1, 156.8/156.5, 139.4, 131.1, 129.0, 128.8, 65.2, 62.5, 62.2, 58.4/57.7, 32.7, 32.0, 29.5, 29.4, 26.6/25.9, 22.8, 14.7, 14.2 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_{\rm R}$ = 8.5 min, minor enantiomer $t_{\rm R}$ = 11.0 min; HRMS (ESI) [M + H]⁺ calcd. for [C₂₄H₃₈ClN₂O₆] 485.2418, found 485.2409.

(5)-Diethyl 1-(1-((4-chlorobenzoyl)oxy)-6-methylheptan-4yl)hydrazine-1,2-dicarboxylate (22e). Colorless oil (38 mg, 77%): $[\alpha]_D^{23} = -8.5$ (c = 2.06 in CHCl₃); IR (thin film, KBr) 3301, 2958, 2869, 1759, 1720, 1405, 1273, 1218, 1105, 1093, 761 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.20–6.13 (brm, 1H), 4.33–4.17 (m, 5H), 4.31 (t, J = 6.2 Hz, 2H), 1.99–0.74 (m, 7H), 1.28–1.27 (m, 6H), 0.90–0.88 (m, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.4/156.9, 156.8/156.4, 139.4, 131.1, 129.0, 128.8, 65.4/65.2, 62.7/62.5, 62.2/ 62.2, 56.4/55.6, 42.0/41.7, 29.5, 25.9, 25.2/25.0, 23.4, 22.3/22.0, 14.6 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 0.5 mL/min; major enantiomer $t_R = 24.2$ min, minor enantiomer $t_R = 30.0$ min; HRMS (ESI) [M + H]⁺ calcd. for [C₂₁H₃₂ClN₂O₆] 443.1949, found 443.1939.

(S)-Diethyl 1-(5-((4-chlorobenzoyl)oxy)-1-(methylthio)pentan-2-yl)hydrazine-1,2-dicarboxylate (22g). Colorless oil (35 mg, 79%): $[\alpha]_D^{23} = 7.9$ (c = 0.71 in CHCl₃); IR (thin film, KBr) 3299, 2980, 2922, 1755, 1719, 1404, 1275, 1121, 1092, 760 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.31 (brm, 1H), 4.35–4.18 (m, 5H), 4.33 (t, J =6.0 Hz, 2H), 2.61 (brs, 2H), 2.09–1.60 (m, 7H), 1.29–1.25 (m, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.6, 156.8, 139.5, 131.1, 129.0, 128.8, 65.2/65.0, 63.0/62.7, 62.4, 56.8/55.5, 37.2/36.7, 28.7, 26.0, 15.5/15.2, 14.6 ppm; HPLC with an AS-H column (*n*-hexane/*i*-PrOH = 95:5), 1.0 mL/min; major enantiomer $t_R = 26.6$ min, minor enantiomer $t_R = 41.5$ min; HRMS (ESI) [M + H]⁺ calcd. for [C₁₉H₂₈ClN₂O₆S] 447.1357, found 447.1347.

(*R*)-Diethyl 1-(1-((4-chlorobenzoyl)oxy)-8-cyanooctan-4-yl)hydrazine-1,2-dicarboxylate (22j). Purified by flash chromatography (5% Et₂O/CH₂Cl₂). Colorless oil (37 mg, 68%): $[\alpha]_D^{23} = -1.9$ (*c* = 1.42 in CHCl₃); IR (thin film, KBr) 3298, 2934, 2869, 2246, 1755, 1717, 1405, 1274, 1232, 1093, 761 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 6.40–6.25 (brm, 1H), 4.32–4.07 (m, 5H), 4.31 (t, *J* = 6.2 Hz, 2H), 2.33 (t, *J* = 6.6 Hz, 2H), 1.90–1.20 (m, 10H), 1.28–1.24 (m, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.5, 156.9/156.5, 139.5, 131.5, 131.1, 128.8, 119.8, 65.1/64.9, 62.9/62.6, 62.3, 58.2/57.1, 32.1/31.8, 29.2, 25.9, 25.6, 25.3, 17.2, 14.6 ppm; HPLC with an AS-H column (*n*hexane/*i*-PrOH = 90:10), 1.0 mL/min; major enantiomer t_R = 47.6 min, minor enantiomer t_R = 36.2 min; HRMS (ESI) [M + H]⁺ calcd. for [C₂₂H₃₁ClN₃O₆] 468.1901, found 468.1891.

Preparation of (S)-Dibenzyl 1-(1-(benzyloxy)-5-((tertbutyldimethylsilyl)oxy)pentan-2-yl)hydrazine-1,2-dicarboxylate (14). To a solution of 13i (227 mg, 0.46 mmol) in CH₂Cl₂ (2.3 mL) was added 2,6-lutidine (110 mL, 0.92 mmol) and TBDMSOTf (160 mL, 0.69 mmol) at -78 °C. After 2 h, MeOH (0.7 mL) was added, and the reaction was warmed to rt. Solvents were removed under vacuum and flash chromatography (25% Et₂O/petroleum ether) yielded 14 (270 mg, 97% yield) as a colorless oil: $[\alpha]_{\rm D}^{26} = 1.3$ (*c* = 0.7 in CHCl₃); IR (thin film, KBr) 3270, 2954, 2928, 2856, 1759, 1716, 1255, 1096 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (s, 15H), 6.71-6.43 (m, 1H), 5.20-5.11 (m, 4H), 4.54-4.34 (m, 3H), 3.67-3.33 (m, 4H), 1.70–1.39 (m, 4H), 0.88 (s, 9H), 0.04 (s, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 156.9, 156.4, 138.1, 136.2, 135.9, 128.6, 128.5, 128.4, 128.2, 128.1, 127.8, 127.7, 72.9, 69.9, 68.4/68.0, 67.8, 67.6, 62.7, 58.2/56.6, 29.3, 26.1, 25.1, 18.5, -5.2 ppm; HRMS (ESI) $[M + H]^+$ calcd. for $[C_{34}H_{47}N_2O_6Si]$ 607.3203, found 607.3212.

Preparation of (S)-*tert***-Butyl (1-(benzyloxy)-5-((***tert***-butyldimethylsilyl)oxy)pentan-2-yl)carbamate (15).** To a slurry of Raney–Nickel (~210 mg, prewashed with MeOH) in MeOH (1 mL), was added AcOH (5 drops) and a solution of 14 (190 mg, 0.31 mmol) in MeOH (4 mL). The reaction was purged with a hydrogen filled balloon for 15 min and stirred under a slightly positive pressure of hydrogen (balloon) at rt for 16 h. The reaction was then filtered

through a short pad of Celite, and the Celite was washed with CH_2Cl_2 . After solvents were removed, the crude product was diluted with CH_2Cl_2 and refiltered through a short pad of Celite. After removal of CH_2Cl_2 under vacuum, the crude product was subjected to Bocprotection.

To a solution of the above crude product (0.31 mmol) in THF (2.1 mL) was added (Boc)₂O (170 mL, 0.74 mmol) and Et₃N (206 mL, 1.48 mmol). The reaction was stirred at rt for 16 h, then concentrated under vacuum to give a residue, which was purified by flash chromatography (25% Et₂O/petroleum ether) to yield **15** (94 mg, 72% yield for two steps) as a colorless oil: $[\alpha]_D^{26} = -10.3$ (c = 0.55 in CHCl₃); IR (thin film, KBr) 3341, 2954, 2857, 1716, 1498, 1365, 1100, 836 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.28 (m, 5H), 4.77 (brs, 1H), 4.54 (d, J = 12.0 Hz, 2H), 4.49 (d, J = 12.0 Hz, 2H), 3.74 (brs, 1H), 3.62 (t, J = 6.0 Hz, 2H), 3.48–3.47 (m, 2H), 1.67–1.52 (m, 4H), 1.44 (s, 9H), 0.89 (s, 9H), 0.46 (s, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 155.8, 138.4, 128.5, 127.7, 127.6, 79.2, 73.3, 72.3, 63.1, 50.3, 29.4, 28.6, 26.1, 18.5, -5.2 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₂₃H₄₂NO₄Si] 424.2883, found 424.2877.

Preparation of (S)-tert-Butyl (5-((tert-butyldimethylsilyl)oxy)-1-hydroxypentan-2-yl)carbamate (16). To a solution of 15 (17 mg, 0.040 mmol) in EtOAc (0.4 mL) was added NaHCO₃ (4 mg, 0.048 mmol) and 10% Pd/C (3.1 mg), and the reaction was stirred under a hydrogen atmosphere at rt for 16 h. The mixture was filtered through a short pad of Celite, and the Celite was washed with EtOAc. The solvent was removed under vacuum, and the residue was purified by flash chromatography (50% EtOAc/petroleum ether) to give 16 (13 mg, 97% yield) as a colorless oil: $[\alpha]_{D}^{24} = -6.0$ (c = 1.73 in CHCl₃); IR (thin film, KBr) 3349, 2954, 2885, 2858, 1690, 1516, 1391, 1366, 1254, 1174, 1100, 836, 776 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.92 (brs, 1H), 3.63–3.52 (m, 5H), 2.93 (brs, 1H), 1.58– 1.47 (m, 4H), 1.41 (s, 9H), 0.87 (s, 9H), 0.03 (s, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 156.8, 79.6, 66.1, 62.9, 52.8, 29.1, 28.5, 27.8, 26.1, 18.4, -5.2 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₆H₃₆NO₄Si] 334.2414, found 334.2429.

Preparation of (S)-tert-Butyl (6-((tert-butyldimethylsilyl)oxy)hex-1-en-3-yl)carbamate (17). NaHCO₃ (60 mg, 0.72 mmol) and Dess-Martin periodinane (152 mg, 0.36 mmol) were added to a solution of 16 (80 mg, 0.24 mmol) in CH₂Cl₂ (1.2 mL) at rt. After 30 min, the reaction was diluted with saturated aqueous Na₂S₂O₃ (0.5 mL), saturated aqueous NaHCO₃ (0.2 mL), and H₂O (0.3 mL). The resulting solution was stirred vigorously until clear and then was diluted further with saturated aqueous Na₂S₂O₃ (2 mL), saturated aqueous NaHCO₃ (2 mL), and H₂O (1 mL) and was extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and the solvents were removed under vacuum. The crude aldehyde was used directly in the Wittig reaction.

To a slurry of Ph_3PCH_3Br (154 mg, 0.43 mmol) in THF (0.8 mL) was added KHMDS (0.5 M in toluene, 0.8 mL, 0.41 mmol), and the resulting yellow suspension was stirred at rt for 2 h and then cooled to -78 °C. A solution of the above crude aldehyde (0.24 mmol) in THF (0.2 mL) was slowly added. After the reaction was stirred at $-78 \text{ }^{\circ}\text{C}$ for 2 h, it was warmed to rt and stirred for another 14 h. Then the reaction was cooled to 0 $^\circ\text{C}$ and quenched with $H_2\text{O}$ and extracted with EtOAc. The organic layer was dried over MgSO₄, filtered, and the solvents were removed under vacuum. The residue was purified by flash chromatography (5% EtOAc/petroleum ether) to give 17 (54 mg, 69% yield for two steps) as a colorless oil: $[\alpha]_D^{25} = 5.6$ (c = 1.0 in CHCl₃); IR (thin film, KBr) 3341, 2955, 2930, 2857, 1705, 1517, 1366, 1252, 1174, 1100, 1005, 835, 776 cm⁻¹; ¹H NMR (400 MHz, $CDCl_3$) δ 5.74 (ddd, J = 16.4, 10.4, 5.6 Hz, 1H), 5.37 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.4 Hz, 1H), 4.62 (brs, 1H), 4.08 (brs, 1H), 3.61 (t, J = 5.6 Hz, 2H), 1.60–1.47 (m, 4H), 1.43 (s, 9H), 0.88 (s, 9H), 0.03 (s, 6H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 139.2, 114.4, 79.3, 62.8, 52.6, 31.5, 28.9, 28.5, 26.1, 18.4, -5.2 ppm; HRMS (ESI) $[M + H]^+$ calcd. for $[C_{17}H_{36}NO_3Si]$ 330.2464, found 330.2465.

Preparation of (5)-tert-Butyl (6-hydroxyhex-1-en-3-yl)carbamate (18). To a solution of 17 (50 mg, 0.15 mmol) in THF (1 mL) was added TBAF (1 M in THF, 0.45 mL, 0.45 mmol) at rt. After 3.5 h, the reaction was quenched with saturated aq NH_4Cl (5

mL) and extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over MgSO₄ and filtered. After removal of the solvent under reduced pressure, the residue was passed through a short pad of silica gel and washed with 7% EtOAc/petroleum ether (15 mL), and the eluent was discarded. Then the silica gel pad was washed with 50% EtOAc/petroleum ether (10 mL), and the solvents were removed under reduced pressure to yield **18** (32 mg, 98% yield) as a colorless oil: $[\alpha]_D^{25} = 7.7$ (c = 1.4 in CHCl₃); IR (thin film, KBr) 3332, 2978, 2933, 2871, 1690, 1527, 1367, 1172, 1059, 993, 918 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 5.73 (ddd, J = 16.4, 10.4, 5.6 Hz, 1H), 5.13 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.4 Hz, 1H), 4.63 (brs, 1H), 4.08 (brs, 1H), 3.63 (t, J = 5.6 Hz, 2H), 2.40 (brs, 1H), 1.62–1.46 (m, 4H), 1.42 (s, 9H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 138.9, 114.7, 79.5, 62.4, 52.6, 31.6, 28.8, 28.5 ppm; HRMS (ESI) [M + H]⁺ calcd. for [C₁₁H₂₂NO₃] 216.1600, found 216.1610.

Preparation of (S)-tert-Butyl 2-oxo-5-vinylpyrrolidine-1carboxylate (19). To a solution of 18 (28 mg, 0.13 mmol) in DMF (2.3 mL) was added PDC (294 mg, 0.8 mmol), and the reaction was stirred at rt for 18 h. The reaction was diluted with H₂O (5 mL), extracted with EtOAc $(3 \times 15 \text{ mL})$, and the combined organic layers were dried with MgSO4. The solution was filtered, and the solvents were removed under reduced pressure. Crude product was purified by flash chromatography (50% EtOAc/petroleum ether) to give 19 (26 mg, 95% yield) as a colorless oil: $\left[\alpha\right]_{D}^{125} = -25.0$ (c = 0.9 in CHCl₃ for 72% ee); Lit.³⁹ $[\alpha]_{\rm D} = -24.3$ (c = 1.07 in CHCl₃ for 72% ee); IR (thin film, KBr) 2980, 2931, 1785, 1752, 1719, 1368, 1308, 1256, 1156, 922, 851, 784 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 5.84 (ddd, J = 17.2, 10.4, 6.0 Hz, 1H), 5.18 (dd, J = 16.0, 0.8 Hz, 1H), 5.17 (dd, J = 11.2, 1.2 Hz, 1H), 4.65-4.61 (m, 1H), 2.61-2.51 (m, 1H), 2.45-2.37 (m, 1H), 2.26–2.16 (m, 1H), 1.83–1.77 (m, 1H), 1.49 (s, 9H) ppm; ¹³C NMR (100 MHz, CDCl₃) δ 174.4, 149.9, 136.9, 115.4, 83.0, 59.7, 31.2, 28.1, 24.4 ppm; HRMS (ESI) $[M + Na]^+$ calcd. for $[C_{11}H_{17}NO_3Na]$ 234.1106, found 234.1113. This data matches that in the literature.

Preparation of Diethyl 1-((35,4R)-3-(((Z)-benzylideneamino)oxy)-1-hydroxyheptan-4-yl)hydrazine-1,2-dicarboxylate (21). To a mixture of catalyst 1a (15 mg, 0.025 mmol) and benzoic acid (3 mg, 0.025 mmol) was added toluene (54 mL), and the mixture was stirred at rt. After 5 min enal 2b (50 mL, 0.375 mmol) was added. After 10 min a solution of 10a (40% in toluene, 114 mL, 0.25 mmol) was added, and the reaction was stirred in the dark. After 21 h (complete consumption of 10a observed by ¹H NMR), the reaction was cooled to 0 °C and catalyst 1a (15 mg, 0.025 mmol) and benzoic acid (3 mg, 0.025 mmol) were added, and the reaction was stirred for 5 min. Oxime 20 (122 mL, 1.125 mmol) was added, and the reaction was stirred at 0 °C for 21 h (complete disappearance of enal peaks in ¹H NMR). MeOH (0.75 mL) and NaBH₄ (21 mg, 0.565 mmol) were added simultaneously, and the reaction was stirred for 15 min and then was quenched with saturated NH₄Cl and extracted with CH₂Cl₂ (3 \times 15 mL). The combined organic layers were dried over MgSO4 and filtered. After removal of solvent under reduced pressure, the residue was purified by flash chromatography (cold column, 20% Et₂O/ CH_2Cl_2) to yield 21 (58 mg, 57% yield) as a colorless oil: $[\alpha]_D^{24} =$ -2.8 (*c* = 0.8 in CHCl₃); IR (thin film, KBr) 3277, 2962, 2873, 1714, 1414, 1253, 1058, 947, 759, 695 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.58-7.56 (m, 2H), 7.38-7.36 (m, 3H), 6.46 (brs, 1H), 4.42-4.18 (m, 6H), 3.80-3.78 (m, 2H), 2.27-1.60 (m, 6H), 1.28-1.25 (m, 6H), 0.91 (t, J = 7.2 Hz, 3H) ppm; ¹³C NMR (100 MHz, CDCl₃) *δ* 157.5/157.0, 156.6/156.1, 149.0, 132.1, 130.1, 128.8, 127.2, 82.0/81.1, 62.9/62.7, 62.4, 60.9/60.0, 59.7, 34.6/34.5, 29.8/29.3, 19.6/ 19.4, 14.5, 14.4, 14.0/13.9 ppm; HPLC with an AD-H column (nhexane/*i*-PrOH = 90:10), 1.0 mL/min; minor enantiomer $t_{\rm R}$ = 12.1 min, major enantiomer $t_{\rm R}$ = 14.4 min, minor diastereomer $t_{\rm R}$ = 18.3 min; HRMS (ESI) $[M + H]^+$ calcd. for $[C_{20}H_{32}N_3O_6]$ 410.2291, found 410.2289.

ASSOCIATED CONTENT

Supporting Information

Reaction optimization, supporting tables, and copies of ¹H, ¹³C and HPLC spectra for compounds 13a-j, 14, 15, 16, 17, 18,

19, **21**, **22a-e**, **22g** and **22j**. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: SBrenner@brooklyn.cuny.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the National Science Foundation (CHE-1148295). The authors gratefully acknowledge Dr. Furong Sun (University of Illinois) for his assistance with mass spectrometry.

REFERENCES

(1) Seminal example: Huang, Y.; Walji, A. M.; Larsen, C. H.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 15051–15053.

(2) Seminal example: Marigo, M.; Schulte, T.; Franzén, J.; Jørgensen, K. A. J. Am. Chem. Soc. **2005**, 127, 15710–15711.

(3) For a recent review, see: Pellissier, H. Adv. Synth. Catal. 2012, 354, 237-294.

(4) For a recent review, see: Albrecht, Ł.; Jiang, H.; Jørgensen, K. A. Angew. Chem., Int. Ed. 2011, 50, 8492–8509.

(5) For examples of dienamines in formal [2 + 2] reactions, see refs 6 and 7. For examples of dienamines as dienophiles in formal [4 + 2] reactions, see refs 8 and 9. For examples of dienamines as dienes in formal [4 + 2] reactions, see refs 10–12.

(6) Albrecht, Ł.; Dickmeiss, G.; Acosta, F. C.; Rodríguez-Escrich, C.; Davis, R. L.; Jørgensen, K. A. J. Am. Chem. Soc. **2012**, 134, 2543–2546.

 (7) Talavera, G.; Reyes, E.; Vicario, J. L.; Carrillo, L. Angew. Chem., Int. Ed. 2012, 51, 4104–4107.

(8) Han, B.; He, Z.-Q.; Li, J.-L.; Li, R.; Jiang, K.; Liu, T.-Y.; Chen, Y.-C. Angew. Chem., Int. Ed. 2009, 48, 5474-5477.

(9) Li, J.-L.; Kang, T.-R.; Zhou, S.-L.; Li, R.; Wu, L.; Chen, Y.-C. Angew. Chem., Int. Ed. 2010, 49, 6418-6420.

(10) Hong, B.-C.; Wu, M.-F.; Tseng, H.-C.; Liao, J.-H. Org. Lett. 2006, 8, 2217-2220.

(11) Hong, B.-C.; Wu, M.-F.; Tseng, H.-C.; Huang, G.-F.; Su, C.-F.; Liao, J.-H. J. Org. Chem. 2007, 72, 8459–8471.

(12) Marcia de Figueiredo, R.; Frölich, R.; Christmann, M. Angew. Chem., Int. Ed. 2008, 47, 1450–1453.

(13) For examples of α -functionalization of dienamines with intramolecular electrophilic positions, see refs 14 and 15. For examples of α -functionalization of dienamines with external electrophiles, see refs 16–19. For examples of γ -functionalization of dienamines, see refs 20–25.

(14) Chen, S.-H.; Hong, B.-C.; Su, C.-F.; Sarshar, S. *Tetrahedron Lett.* **2005**, *46*, 8899–8903.

(15) Marqués-López, E.; Herrera, R. P.; Marks, T.; Jacobs, W. C.; Könning, D.; Marcia de Figueiredo, R.; Christmann, M. Org. Lett. 2009, 11, 4116–4119.

(16) Utsumi, N.; Zhang, H.; Tanaka, F.; Barbas, C. F., III Angew. Chem., Int. Ed. 2007, 46, 1878–1880.

(17) Vesely, J.; Dziedzic, P.; Córdova, A. Tetrahedron Lett. 2007, 48, 6900-6904.

(18) Han, B.; Xiao, Y.-C.; He, Z.-Q.; Chen, Y.-C. Org. Lett. 2009, 11, 4660–4663.

(19) Han, B.; Xiao, Y.-C.; Yao, Y.; Chen, Y.-C. Angew. Chem., Int. Ed. **2010**, 49, 10189–10191.

(20) Bertelsen, S.; Marigo, M.; Brandes, S.; Dinér, P.; Jørgensen, K. A. J. Am. Chem. Soc. **2006**, 128, 12973–12980.

(21) Liu, K.; Chougnet, A.; Woggon, W.-D. Angew. Chem., Int. Ed. 2008, 47, 5827–5829.

(22) Volz, N.; Bröhmer, M. C.; Nieger, N.; Bräse, S. Synlett 2009, 550–553.

- (23) Bencivenni, G.; Galzerano, P.; Mazzanti, A.; Bartoli, G.;
- Melchiorre, P. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20642-20647. (24) Bergonzini, G.; Vera, S.; Melchiorre, P. Angew. Chem., Int. Ed.
- 2010, 49, 9685–9688. (25) Stiller, J.; Marqués-López, E.; Herrera, R. P.; Fröhlich, R.; Strohmann, C.; Christmann, M. Org. Lett. 2011, 13, 70–73.

(26) For a recent review, see: Tolman, J. A.; Faulkner, M. A. *Expert* Opin. Pharmacother. **2009**, 10, 3077–3089.

(27) Zhao, G.-L.; Córdova, A. Tetrahedron Lett. 2006, 47, 7417–7421.

(28) See the Supporting Information for full details.

(29) γ -Amino aldehydes were susceptible to decomposition during purification via column chromatography, and so were reduced in situ to generate readily isolable γ -amino alcohols.

(30) Wei, Z. Y.; Knaus, E. E. Synlett 1994, 345-346.

(31) Bertelsen, S.; Dinér, P.; Johansen, R. L.; Jørgensen, K. A. J. Am. Chem. Soc. 2007, 129, 1536–1537.

(32) Lin, Q.; Meloni, D.; Pan, Y.; Xia, M.; Rodgers, J.; Shepard, S.; Li, M.; Galya, L.; Metcalf, B.; Yue, T.-Y.; Liu, P.; Zhou, J. *Org. Lett.* **2009**, *11*, 1999–2002.

(33) Mathre, D.; Jones, T.; Xavier, L.; Blacklock, T.; Reamer, R.; Mohan, J.; Jones, E.; Hoogsteen, K.; Baum, M.; Grabowski, E. J. Org. Chem. **1991**, 56, 751–762.

(34) Sepe, V.; D'Auria, M. V.; Bifulco, G.; Ummarino, R.; Zampella, A. *Tetrahedron* **2010**, *66*, 7520–7526.

(35) Cardani, S.; De Toma, C.; Gennari, C.; Scolastico, C. *Tetrahedron* **1992**, *48*, 5557–5564.

(36) Barbazanges, M.; Meyer, C.; Cossy, J. Org. Lett. 2008, 10, 4489–4492.

(37) Appayee, C.; Brenner-Moyer, S. E. Org. Lett. 2010, 12, 3356–3359.

(38) Ramón, R. S.; Bosson, J.; Díez-González, S.; Marion, N.; Nolan, S. P. J. Org. Chem. **2010**, 75, 1197–1202.

(39) Hoye, A. T.; Wipf, P. Org. Lett. 2011, 13, 2634-2637.

Note